Vistin Pharma ASA

OB:VISTN Stock Report

Market Cap: NOK 1.1b

Vistin Pharma Past Earnings Performance

Past criteria checks 4/6

Vistin Pharma has been growing earnings at an average annual rate of 43.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 15.6% per year. Vistin Pharma's return on equity is 19.7%, and it has net margins of 14.4%.

Key information

43.4%

Earnings growth rate

43.5%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate15.6%
Return on equity19.7%
Net Margin14.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Sep 18
Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

Feb 23
Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Sep 09
A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Aug 25
Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

Mar 15
Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Feb 20
We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

Jan 29
Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Jan 08
The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Dec 16
Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

Nov 26
Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

Revenue & Expenses Breakdown

How Vistin Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OB:VISTN Revenue, expenses and earnings (NOK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2442761840
30 Jun 2444168840
31 Mar 2444156940
31 Dec 2343846820
30 Sep 2343945790
30 Jun 2341014740
31 Mar 233737710
31 Dec 22305-5700
30 Sep 22272-15710
30 Jun 22243-7690
31 Mar 222411660
31 Dec 2127925650
30 Sep 2126526630
30 Jun 2125730640
31 Mar 2126343820
31 Dec 20254-97640
30 Sep 20246-102630
30 Jun 20259-46630
31 Mar 20247-67460
31 Dec 1922866610
30 Sep 192124700
30 Jun 19196-59690
31 Mar 19190-72690
31 Dec 18201-68700
30 Sep 18200-16700
30 Jun 18194-8650
31 Mar 181868620
31 Dec 171755580
30 Sep 1716810500
30 Jun 171607490
31 Mar 1717014480
31 Dec 1617316470
30 Sep 16393401050
30 Jun 16446461230
31 Dec 15376331080
31 Dec 14361-62960
31 Dec 133478940

Quality Earnings: VISTN has high quality earnings.

Growing Profit Margin: VISTN's current net profit margins (14.4%) are higher than last year (10.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: VISTN's earnings have grown significantly by 43.4% per year over the past 5 years.

Accelerating Growth: VISTN's earnings growth over the past year (37.9%) is below its 5-year average (43.4% per year).

Earnings vs Industry: VISTN earnings growth over the past year (37.9%) exceeded the Pharmaceuticals industry 10.2%.

Return on Equity

High ROE: VISTN's Return on Equity (19.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y